Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer. - Wikidata - awgldk - TriplyDB

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer.

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer.

http://www.wikidata.org/entity/Q37388593

about

Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients.Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma.

P2860

Q33389316-C8F880FC-A3F0-4661-8EF5-E151753E44B2 Q35845236-E94D9F5E-436E-4FE2-9652-517BC12ECE0B

P2860

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer.

http://www.wikidata.org/entity/Q37388593

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer.

@en

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer.

@nl

type

label

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer.

@en

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer.

@nl

prefLabel

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer.

@en

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer.

@nl

P1433

Q37388593-58DCE422-C961-4AA5-8994-BC185D9CD600

P1476

Q37388593-F12C9AFA-AA94-406D-B569-A917A9834F9F

P2093

Q37388593-16195BD0-C4E3-403A-A04A-1DFF2DF1FB5C

Q37388593-C57C060A-B598-4E5A-943F-E94C11F92D91

Q37388593-E81D4EB9-7FAC-4AB6-83DD-FD1BE4AE724E

P2860

Q37388593-093F7EF9-C850-473A-A1A0-FC6E709B689E

Q37388593-0C834DB3-B014-4594-9603-17FBBCF27471

Q37388593-18DD5CE2-A45E-45EF-9050-3AC59FE5C1FA

Q37388593-1AD1F18C-219C-441C-B833-256D9CA97CA7

Q37388593-1F4DC2E1-0AB1-4F5A-82D1-A305B09DB274

Q37388593-1F83652B-861D-4F00-A7BA-3B9064A3CA04

Q37388593-2006B00B-C63F-4E5C-9873-7B2488FC1E33

Q37388593-35E2D92F-36A7-4D64-BC4E-D83520E4C37D

Q37388593-418C280E-077E-4E86-9947-BBE802FA7B02

Q37388593-4C27B758-1C19-4FD3-8E33-9E35D06C8AA0

P304

Q37388593-9E81906C-ED84-4753-A19A-0034BAAF297C

P31

Q37388593-74DBCE64-6EA3-4B2E-82C7-A34728BB6185

P356

Q37388593-1523F3EF-6008-4A2B-968A-B3A986D1DBE9

P478

Q37388593-B3924FAE-02DB-43F6-A073-216B7ABE5AF8

P577

Q37388593-3BD50ABA-1A51-4781-81A4-EC3199C93AA6

P698

Q37388593-780100C4-B63E-47E6-A6A3-98F5447B5829

P921

Q37388593-5123A507-AD7C-46A0-BCD1-1C0FA8D7C117

P932

Q37388593-A18370DA-612A-436D-B7F0-A4B7C792D2CE

P356

P1433

Therapeutics and Clinical Risk Management

P1476

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer

@en

P2093

Filippo de Marinis

http://www.w3.org/2001/XMLSchema#string

Serena Ricciardi

http://www.w3.org/2001/XMLSchema#string

Silverio Tomao

http://www.w3.org/2001/XMLSchema#string

P2860

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Cancer statistics, 2005

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer.

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial.

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.

Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer.

P304

781-787

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S3195

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19851525

http://www.w3.org/2001/XMLSchema#string

P921

P932

2762436

http://www.w3.org/2001/XMLSchema#string